DRI Healthcare Trust (DHT-UN) Q1 2025 earnings summary

Executive summary

• Internalization of management completed with a $49 million payment, expected to save $200 million over 10 years, improve governance, and align interests with unitholders.

• Achieved second highest quarterly cash receipts and adjusted EBITDA since IPO, with portfolio assets performing as anticipated and growth assets contributing significantly.

• Reactivated normal course issuer bid (NCIB), allowing repurchase of up to 3,148,536 units from May 2025 to May 2026 to capitalize on undervaluation.

• Leadership transition: Gary Collins to become Executive Chairman, Ali Hedayat to assume full-time CEO role.

Financial highlights

• Q1 2025 total cash receipts were $62.0 million, down 2% year-over-year but up 39% sequentially from Q4 2024.

• Total income reached $44.0 million, up 5% year-over-year.

• Adjusted EBITDA was $51.7 million (83% margin), down 7% year-over-year; would have been $55.6 million (90% margin) excluding $3.9 million in non-recurring internalization costs.

• Adjusted cash earnings per unit were $0.43 for Q1 2025 and $2.13 for the trailing 12 months.

• Cash and cash equivalents stood at $55.7 million, with $45 million in royalty receivables and $312.5 million in available credit.

Outlook and guidance

• Internalization expected to generate over $200 million in cumulative savings over 10 years and be accretive per unit.

• Quarterly distribution remains $0.10 per unit, targeting 20%-30% of free cash flow.

• Robust pipeline of over $3 billion in potential opportunities under evaluation.

• Expect gradual return to low single-digit growth for Omidria in H2 2025, with stabilization of demand and new commercial initiatives.

• Management remains focused on acquiring new pharmaceutical royalty streams and capitalizing on a robust pipeline.